A Case of Thyroid Carcinoma Showing Thymus-Like Differentiation With Breast Cancer Susceptibility Gene 2 Mutation: A Case Report and Literature Review

Masashi Kuroki 1, Hirofumi Shibata 1, Ryota Iinuma 1, Hiroshi Okuda 1, Toshimitsu Osashi 1, Takenori Ogawa 1, Yukio Horikawa 2

1. Otolaryngology - Head and Neck Surgery, Gifu University Graduate School of Medicine, Gifu, JPN
2. Clinical Genetics Center, Gifu University Hospital, Gifu, JPN

Corresponding author: Yukio Horikawa, yhorikawa@gifu-u.ac.jp

Abstract

Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor that originates from ectopic thymic or residual embryonic tissues. CASTLE is specified as a synonym for intrathyroidal thymic carcinoma.

The patient is a 66-year-old male. Surgery was performed on the thyroid tumor with tracheal infiltration, and pathological examination revealed CASTLE. Multidisciplinary treatment, including chemoradiotherapy, was performed for recurrent tumors, and he has been alive for 90 months since the initial treatment. The cancer genome panel identified mutations in AT-rich interaction domain 1A (ARID1A) and breast cancer susceptibility gene 2 (BRCA2), but there were no available clinical trials or recommended drugs. BRCA2 may be involved in CASTLE. Herein, we review the literature and report the treatment method and gene mutation for recurrent metastatic cases of CASTLE, for which standard treatment has not been established.

Categories: Genetics, Otolaryngology, Pathology
Keywords: arid1a, brca2, cancer genome panel, thyroid cancer, intrathyroidal thymic carcinoma, castle

Introduction

Carcinoma showing thymus-like differentiation (CASTLE) is a rare malignant tumor with thymic epithelial differentiation, often originating from the thyroid gland. The fourth edition of the World Health Organization (WHO) classification specifies that it is a synonym for intrathyroidal thymic carcinoma in thyroid tumors [1]. We encountered a case of CASTLE originating in the thyroid gland and performed a cancer genome panel.

Case Presentation

A 66-year-old male visited the internal medicine department with hoarseness and a cough. Ultrasound revealed a hypoechoic tumor with extraglandular invasion in the left lobe of the thyroid, and the patient was referred to our hospital. The patient had a history of diabetes, dyslipidemia, hypertension, and hyperuricemia and had no family history of cancer.

Laryngeal endoscopy revealed paralysis of the left vocal cord and confirmed that the tumor protruded into the lumen of the left trachea (Figure 1a). Blood tests revealed normal levels of thyroid hormones, thyroglobulin, and various markers. Computed tomography revealed a low-density, ill-defined tumor measuring 21 × 21 mm in the lower pole of the left lobe of the thyroid gland. Tumor infiltration of the trachea was suspected. Swelling of the left paratracheal lymph node was also observed (Figure 1b). Fine needle aspiration cytology revealed atypical cells with a large nuclear/cytoplasmic (N/C) ratio and increased nuclear chromatin levels but almost no papillary agglomeration or follicular formation. An open biopsy was performed because it was difficult to distinguish. Based on the results of the biopsy, poorly differentiated thyroid cancer, neuroendocrine tumor, and thymus-like tumor were suspected. The tumor was staged as cT4aN1aM0, according to the classification of thyroid cancer. Total thyroidectomy, bilateral D1 dissection, cervical tracheal resection, and tracheal reconstruction were performed.
FIGURE 1: Preoperative and intraoperative findings

a: Laryngeal endoscopy reveals paralysis of the left vocal cord, and arrowheads indicate a tumor protruding into the lumen of the left trachea. b: Computed tomography shows a 21 × 21 mm-sized low-concentration mass with an unclear boundary in the lower pole of the left lobe of the thyroid gland, and infiltration into the trachea was suspected. Arrowheads indicate the tumor region. Swelling of the left paratracheal lymph node was also observed.

Postoperative histopathological examination revealed that tumor cells with a high N/C ratio had infiltrated and proliferated in the form of alveolar lesions (Figure 2a). Hyaline and lymphocyte-rich stroma infiltrated around the tumor follicle. Immunohistochemical staining showed cytokeratin (CK) AE1/AE3 (+), p63 (+), cluster of differentiation 5 (CD5) (+), S100 protein (S100P) (-), thyroid transcription factor 1 (TTF-1) (-), thyroglobulin (-), calcitonin (-), parathyroid hormone (PTH) (-), synaptophysin partially weak (+), chromogranin A (-), and CD56 (-), and MIB-1 index was 10%-30% (Figure 2b). Based on these results, the tumor was diagnosed as CASTLE (pT4a, pEx2, and pN1b).
Thirty-five months after the first operation, recurrence was detected in the left neck and mediastinal lymph nodes. Left neck and mediastinal dissections were performed. Re-recurrence occurred 45 and 62 months after the first surgery, and surgical resections were performed. However, re-recurrence occurred 77 months after the first surgery. Next-generation sequencing with the OncoGuide™ NCC Oncopanel System (National Cancer Center, Tokyo, Japan, and Sysmex Corporation, Kobe, Japan) was performed to investigate tumor-specific mutations and identify appropriate chemotherapeutic drugs.

Sequencing was performed using formalin-fixed paraffin-embedded tissue from the metastatic lymph nodes, with patient consent. A total of 114 cancer-related mutations were detected using the OncoGuide™ NCC Oncopanel System. The biomarker findings were stable microsatellite status and 0.8 mutations/megabase for...
tumor mutational burden. Gene mutations in AT-rich interaction domain 1A (ARID1A) and breast cancer susceptibility gene 2 (BRCA2) were found, and the variant allele frequencies were 32% and 40%, respectively. The ATR inhibitors BAY1895344 and M5520 (CX970) have been suggested to be effective against ARID1A mutations. However, there were no available clinical trials or recommended drugs (Table 1).

**Biomarker findings**

| Microsatellite status | Stable |
| Tumor mutational burden | 0.8 mutations/megabase |

**Genomic findings**

| Gene       | Alteration | Variant allele frequency (%) | Therapies with clinical benefit |
|------------|------------|------------------------------|-------------------------------|
| ARID1A     | A347Fs*53  | 32                           | None                          |
| BRCA2      | V2109I     | 40                           | None                          |

**TABLE 1: Cancer genome panel findings**

The biomarker findings were stable microsatellite status and 0.8 mutations/megabase for the tumor mutational burden. Mutations in AT-rich interaction domain 1A (ARID1A) and breast cancer susceptibility gene 2 (BRCA2) were found, with allele frequencies of 32% and 40%, respectively.

Subsequently, concurrent chemoradiotherapy with cisplatin was performed, and the patient was alive with cancer 90 months after the first surgery.

**Discussion**

CASTLE is defined as a malignant epithelial tumor of the thyroid gland with thyroid epithelial differentiation and an ectopic thyroid tumor in the thyroid gland [1]. CASTLE is a synonym for intrathyroidal thymic carcinoma, and other names are mentioned, including intrathyroidal epithelial thymoma, carcinoma showing thymus-like differentiation, primary thyroid thymoma, carcinoma showing thymus-like features, lymphoepithelioma, and CD5-positive thyroid carcinoma [2-7]. There have been some case reports of CASTLE in Japan and China. However, this frequency is rare, with 0.083% of thyroid tumors in Japan and 0.15% of thyroid tumors in China [7,8]. Most of the primary sites are the thyroid glands, but some papers have reported parotid gland-oriented cases [9-11]. The subjective symptoms were a neck mass and hoarseness due to recurrent laryngeal nerve palsy, and blood tests showed normal thyroid hormone levels [12].

The histopathological findings were similar to those of mediastinal thymic carcinoma accompanied by squamous epithelial characteristics. The histological grade is lower, and nuclear atypia is milder than that of squamous cell carcinoma [1]. Immunohistochemical staining was positive for CD5, c-kit, p65, BCL2, and calcitriol and negative for TTF-1 and thyroglobulin, which are positive for differentiated thyroid cancers [13]. In addition, as in this case, CASTLE may have neuroendocrine properties, such as positive synaptophysin and chromogranin A [7,14]. CASTLE is histologically classified as squamous cell carcinoma type, lymphoepithelioma or basaloid type, and neuroendocrine carcinoma type [7]. In thymic cancer, squamous cell carcinoma type and basaloid carcinoma type have a better prognosis than lymphoepithelial-like carcinoma and neuroendocrine carcinoma type [15]. Based on partial synaptophysin-positive data, this case was correlated with the neuroendocrine tumor type.

Although the standard treatment for CASTLE has not been established, surgical treatments are performed in most resectable cases. Many reports have indicated the effectiveness of postoperative radiotherapy in locally advanced cases [12,16]. Chemotherapy is often selected according to the treatment of thymic carcinoma, but Lorenz et al. [10] reported a case of partial response to pembrolizumab. The prognosis after curative resection is relatively good, and the disease-specific survival rate is 90% at five years and 82% at 10 years [12].

There are only five reports of genetic testing for CASTLE (Table 2). Wang et al. [17] and Rajeshwari et al. [18] identified mutations in the epidermal growth factor receptor (EGFR), and Veits et al. [19] identified mutations in EGFR and platelet-derived growth factor receptor (PDGFR). Ishikawa et al. [9] performed whole-exome sequencing and identified somatic mutations in Fraser extracellular matrix complex subunit 1 (FRAS1)-related extracellular matrix 2 (FREM2), CDC-like kinase 3 (CLK3), discs large (DLG)-associated protein 1 (DLPAP1), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 (NOX1), and pregnancy-specific beta-1-glycoprotein 9 (PSG9). Wong et al. [11] performed an Oncomine® Comprehensive Cancer Panel (143 genes) and detected germline mutations in peroxisome proliferator-
activated receptor γ (PPARG), BRCA2, and Notch receptor 1 (NOTCH1). BRCA2 mutation was detected, as in our case, but neither of the cases reported by Wong et al. [11] nor our case had a family history of cancer. Principe et al. [20] reported a case in which tumor control was possible using the PARP inhibitor olaparib for metastatic thymoma with BRCA2 mutation. Treatment targeting BRCA2 may also be effective for CASTLE with BRCA2 mutations. However, the frequency of the occurrence of CASTLE is extremely low, and it is hoped that cases involving genetic testing will be more common in the future.

| Author          | Year | Primary | Gene     | Nucleotide | Protein |
|-----------------|------|---------|----------|------------|---------|
| Veits et al. [19] | 2014 | Thyroid | EGFR     | c.2361G>A  | p.Q787Q |
|                 |      |         | PDGFR    | c.1701A>G  | p.P567P |
| Wang et al. [17] | 2015 | Thyroid | EGFR     | c.2363G>A  | p.Q787Q |
| Wong et al. [11] | 2018 | Parotid | BRCA2    | -          | p.I2490T|
|                 |      |         | NOTCH1   | -          | p.T2455A|
| Rajeshwari et al. [18] | 2018 | Thyroid | EGFR     | -          | p.T790M |
| Ishikawa et al. [9] | 2021 | Parotid | FREM2    | c.2581G>T  | p.V861F |
|                 |      |         | CLK3     | c.1128C>A  | p.F376L |
|                 |      |         | DLGAP1   | c.882G>T   | p.K294N |
|                 |      |         | NOX1     | c.493G>A   | p.V165M |
|                 |      |         | PSG9     | c.430+4A>T | -       |
| Our case        |      | Thyroid | ARID1A   | c.1037_10381nsG | p.A347fs*53 |
|                 |      |         | BRCA2    | c.6325G>A  | p.V2109I |

**TABLE 2: Report on carcinoma showing thymus-like differentiation (CASTLE) gene mutation**

Wang et al. [17] and Rajeshwari et al. [18] identified mutations in epidermal growth factor receptor (EGFR), and Veits et al. [19] identified mutations in EGFR and platelet-derived growth factor receptor (PDGFR). Ishikawa et al. [9] performed whole-exome sequencing and detected somatic mutations in Fraser extracellular matrix complex subunit 1 (FRAS1)-related extracellular matrix 2 (FREM2), CDC-like kinase 3 (CLK3), discs large (DLG)-associated protein 1 (DLGAP1), nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 1 (NOX1), and pregnancy-specific beta-1-glycoprotein 9 (PSG9). Wong et al. [11] performed oncogene panel tests and detected germline mutations in peroxisome proliferator-activated receptor γ (PPARG), BRCA2, and Notch receptor 1 (NOTCH1).

**BRCA2**: breast cancer susceptibility gene 2, **ARID1A**: AT-rich interaction domain 1A

**Conclusions**

In this report, we described a case of CASTLE originating from the thyroid gland and detailed a cancer gene panel for recurrent lesions. Gene mutations in ARID1A and BRCA2 were identified; however, there were no available clinical trials or recommended drugs. This is the second report of CASTLE with a BRCA2 mutation. For this disease, for which standard treatment has not been established, the accumulation of cases including genetic testing is awaited in the future.

**Additional Information**

**Disclosures**

**Human subjects:** Consent was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

**References**
1. Lloyd RV, Osamura RY, Klöppel G, Rosai J: WHO classification of tumours of endocrine organs, WHO classification of tumours, 4th edition, volume 10. IARC Publications. 2017, 125-6.

2. Miyauchi A, Kuma K, Matsuura F, Matsuyahashi S, Kobayashi A, Tamai H, Katayama S: Intrathyroidal epithelial thymoma: an entity distinct from squamous cell carcinoma of the thyroid. World J Surg. 1985, 9:128-35. 10.1007/BF01666263

3. Chan JK, Rosai J: WHO classification of tumours of endocrine organs, WHO classification of tumours, 4th edition, volume 10. IARC Publications. 2017, 125-6.

4. Miyauchi A, Kuma K, Matsuzuka F, Matsubayashi S, Kobayashi A, Tamai H, Katayama S: Intrathyroidal epithelial thymoma: an entity distinct from squamous cell carcinoma of the thyroid. World J Surg. 1985, 9:128-35. 10.1007/BF01656263

5. Jochum W, Padberg BC, Schröder S: [Lymphoepithelial carcinoma of the thyroid gland. A thyroid gland carcinoma with thymus-like differentiation]. Pathologe. 1994, 15:561-5. 10.1007/s002920050068

6. Kakudo K, Bai Y, Ozaki T, Homma K, Ito Y, Miyauchi A: Intrathyroidal epithelial thymoma (ITET) and carcinoma showing thymus-like differentiation (CASTLE): CD5-positive neoplasms mimicking squamous cell carcinoma of the thyroid. Histol Histopathol. 2013, 28:543-56. 10.14670/HHP-28.543

7. Ito Y, Miyauchi A, Minato H, Yokoyama S, Kuma S, Kojima M: Intrathyroidal epithelial thymoma/carcinoma showing thymus-like differentiation; comparison with thymic lymphoepithelioma-like carcinoma and a possibility of development from a multipotential stem cell. APMIS. 2013, 121:523-30. 10.1111/apm.12017

8. Yamazaki M, Fujii S, Daiko H, Hayashi R, Ochiai A: Carcinoma showing thymus-like differentiation (CASTLE) with neuroendocrine differentiation. Pathol Int. 2008, 58:775-9. 10.1111/j.1440-1827.2008.02510.x

9. Suster S, Rosai J: Carcinoma showing thymus-like differentiation. A clinicopathologic study of 60 cases. Cancer. 1991, 67:1025-32. 10.1002/1097-0142(19910215)67:4<1025::aid-cncr2820670427>3.0.co;2-f

10. Sun T, Wang Z, Wang J, Wu Y, Li D, Ying H: Outcome of radical resection and postoperative radiotherapy for thyroid carcinoma showing thymus-like differentiation. World J Surg. 2011, 35:1840-6. 10.1007/s00268-011-1151-2

11. Principe DR, Kamath SD, Munshi HG, Mohindra NA: Metastatic thymoma harboring a deleterious BRCA2 mutation derives durable clinical benefit from olaparib. Oncologist. 2020, 25:501-5. 10.1634/theoncologist.2019-0393